EDAP TMS SA Sponsored ADR EDAP 深 沪
已收盘 02-06 16:00:00 美东时间
4.73
+0.730
+18.25%
华盛通- 最 高4.87
- 今 开4.06
- 成交量 9.31万股
- 最 低 4.06
- 昨 收 4.00
- 总市值 1.77亿
- 52周最高 4.87
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 1.21
- 委 比 28.30%
- 总股本 3739.21万
- 历史最高 12.65
- 量 比 0.96
- 振 幅 20.25%
- 历史最低 1.15
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EDAP TMS Expects Q4 HIFU Revenue To Range Between $12.9M - $13.3M, Annual 2025 Global HIFU Revenue Between $36.7M - $37.2M
EDAP TMS SA (Nasdaq: EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced select preliminary unaudited financial and operational results highlighting record fourth quarter
01-12 20:47
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU
EDAP TMS SA received FDA 510(k) clearance for new ultrasound imaging and workflow enhancements for its Focal One HIFU system, enhancing treatment planning and user-interface. The advanced imaging engine supports AI-driven algorithms for tissue ablation visualization. CEO Ryan Rhodes highlighted the company's commitment to innovation and global leadership in prostate cancer therapy.
2025-11-20 12:30
EDAP to Present at Piper Sandler 37th Annual Healthcare Conference
EDAP TMS SA, a global leader in robotic energy-based therapies, announced that CEO Ryan Rhodes and CFO Ken Mobeck will present and host 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York City. The event features a fireside discussion and investor meetings, with a webcast available live and archived on the Company’s website. EDAP specializes in minimally invasive medical devices, including...
2025-11-18 12:00
EDAP TMS S.A. Earnings Call: Growth Amid Challenges
EDAP TMS S.A. (($EDAP)) has held its Q3 earnings call. Read on for the main hig...
2025-11-08 09:05
Edap TMS Q3 EPS $(0.16) Beats $(0.26) Estimate, Sales $16.128M Beat $15.140M Estimate
Edap TMS (NASDAQ:EDAP) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 38.46 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the same
2025-11-06 20:34
EDAP to Present at Jefferies Global Healthcare Conference in London
EDAP TMS SA’s CEO, Ryan Rhodes, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. The presentation will take place from 4:30-4:55 pm GMT and include 1x1 investor meetings. A live and archived webcast will be available via the provided link. EDAP TMS SA specializes in robotic energy-based therapies, specifically the Focal One® for prostate focal therapy.
2025-11-04 12:00
EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis
EDAP TMS S.A. (($EDAP)) announced an update on their ongoing clinical study. St...
2025-10-28 04:59
EDAP TMS secures €36 mln credit facility from European Investment Bank
EDAP TMS SA (NASDAQ:EDAP) said on Monday it entered into a €36 million multi-tranche credit facility with the European Investment Bank to support the expansion of its Focal One robotic high-intensity ...
2025-10-20 20:50
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU
EDAP TMS SA has secured a €36 million credit facility from the European Investment Bank to expand its Focal One Robotic HIFU platform. The funds will support global growth and new clinical applications. The facility includes three tranches with varying interest rates and warrants for EIB. Ryan Rhodes highlighted the strategic importance for meeting global patient demand for non-invasive treatments. EDAP expects to draw the first €11 million tranc...
2025-10-20 12:30
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
EDAP TMS SA, a global leader in robotic energy-based therapies, highlighted its non-invasive Focal One Robotic HIFU treatment during Prostate Cancer Awareness Month. The therapy was featured on *Health Uncensored with Dr. Drew* on the Lifetime Network, reaching millions nationwide. Patient Peter D. shared his positive experience, emphasizing minimal disruption to daily life. His urologist, Dr. Eric Giesler, noted Focal One's ability to target pro...
2025-09-30 11:00
